drugset / Trial / NCT03152435
EGFR CART Cells for Patients With Metastatic Colorectal Cancer
Phase 1/2
Unknown
20 enrolled
Shenzhen Second People's Hospital
The Beijing Pregene Science and Technology Company, Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR CART) cells in metastatic patients with colorectal cancer.
Timeline
- Start
- 2017-06-15
- Primary completion
- 2019-09
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EGFR CART | Cell therapy | — | — |